Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Policy / Regulatory

Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List

Fineline Cube Sep 29, 2024

Researchers in the U.S. have compiled a list of drugs that are anticipated to be...

Company Drug

Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA

Fineline Cube Sep 29, 2024

Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its...

Company Drug

AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA

Fineline Cube Sep 29, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...

Company Deals

Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development

Fineline Cube Sep 29, 2024

Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has...

Company

HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility

Fineline Cube Sep 29, 2024

HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...

Company Deals

Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation

Fineline Cube Sep 29, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...

Company Drug

Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company

3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline

Fineline Cube Sep 29, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...

Policy / Regulatory

China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions

Fineline Cube Sep 29, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Policy / Regulatory

China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel

Fineline Cube Sep 29, 2024

The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...

Company Deals

OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor

Fineline Cube Sep 28, 2024

Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution...

Company Drug

Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...

Company Drug

AstraZeneca’s Tagrisso Secures FDA Approval for Unresectable Stage III EGFRm NSCLC

Fineline Cube Sep 27, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Deals

Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...

Company Deals

Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation

Fineline Cube Sep 27, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...

Company Deals

FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism

Fineline Cube Sep 27, 2024

The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...

Policy / Regulatory

Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024

Fineline Cube Sep 27, 2024

The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...

Company Deals

Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA

Fineline Cube Sep 27, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company

China’s Pharmaceutical Industry Sees Mixed Results in H1 2024, CAPEM Data Reveals

Fineline Cube Sep 27, 2024

The China Association of Pharmaceutical Enterprises Management (CAPEM) has released a comprehensive set of data...

Posts pagination

1 … 252 253 254 … 627

Recent updates

  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
  • Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Company Drug

Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.